A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 383-390

  Strosberg, J R ^a   Chan, J A ^a   Ryan, D P ^c   Meyerhardt, J A ^b   Fuchs, C S ^b   Abrams, T ^b   Regan, E ^b   Brady, R ^b   Weber, J ^a   Campos, T ^a   Kvols, L K ^a   Kulke, M H ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carcinoid; Neuroendocrine tumors

Indexed keywords

GANITUMAB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER SURVIVAL; CARCINOID; COHORT ANALYSIS; COLITIS; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPONATREMIA; IMMUNOGENICITY; INFECTION; INFUSION RELATED REACTION; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

CARCINOID; NEUROENDOCRINE TUMORS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 84879411446     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0390     Document Type: Article

References (25)

1. Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S et al. 2009 AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics 8 1095-1105. (doi:10.1158/1535-7163. MCT-08-1171)
2. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A et al. 2011 Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30 2730-2740. (doi:10.1038/onc.2010.640)
3. Haluska P, Carboni JM, Ten Eyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM & Erlichman C 2008 HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Molecular Cancer Therapeutics 7 2589-2598. (doi:10.1158/1535-7163.MCT-08-0493)
4. Hopfner M, Baradari V, Huether A, Schofl C & Scherubl H 2006 The insulinlike growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocrine-Related Cancer 13 135-149. (doi:10.1677/erc.1.01090)
5. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA et al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 1199-1203. (doi:10.1126/science.1200609)
6. Kindler HL, Richards DA, Garbo LE, Stephenson JJ, Jr, Rocha-Lima CM, Safran H, Chan D, Kocs DM, Galimi F, McGreivy J et al. 2012 A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology 23 2834-2842. (doi:10.1093/annonc/mds142)
7. Klimstra DS, Modlin IR, Coppola D, Lloyd RV & Suster S 2010 The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39 707-712. (doi:10.1097/MPA. 0b013e3181ec124e)
8. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R & Yao JC 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 4762-4771. (doi:10.1200/JCO.2004.04.024)
9. Kulke MH, Stuart K, Enzinger PC, Clark JW, Muzikansky A, Vincitore M, Michelini A & Fuchs CS 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 24 401-406. (doi:10.1200/JCO.2005.03. 6046)
10. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 26 3403-3410. (doi:10.1200/JCO.2007.15.9020)
11. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ et al. 2011 Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of Clinical Oncology 29 934-943. (doi:10.1200/JCO.2010.33.2056)
12. Kulke MH, Benson AB, III, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L et al. 2012 Neuroendocrine tumors. Journal of the National Comprehensive Cancer Network 10 724-764.
13. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J & Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a longacting somatostatin analogue. New England Journal of Medicine 315 663-666. (doi:10.1056/NEJM198609113151102)
14. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG & Klaassen D 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326 519-523. (doi:10.1056/NEJM199202203260804)
15. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM et al. 2011 Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378 2005-2012. (doi:10.1016/S0140- 6736(11)61742-X)
16. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501-513. (doi:10.1056/NEJMoa1003825)
17. Reidy-Lagunes DL, Vakiani E, Segal MF, Hollywood EM, Tang LH, Solit DB, Pietanza MC, Capanu M & Saltz LB 2012 A phase 2 study of the insulinlike growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118 4795-4800. (doi:10.1002/cncr.27459)
18. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO. 2009.22.8510)
19. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J & Kvols L 2011 First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 268-275. (doi:10.1002/cncr.25425)
20. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS et al. 2009 Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. Journal of Clinical Oncology 27 5800-5807. (doi:10.1200/JCO.2009. 23.6745)
21. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm BO, Adler G & Seufferlein T 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Research 60 4573-4581. (doi:10.1016/S0016-5085(00)84296-1)
22. Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R & Fehmann HC 2000 mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. European Journal of Clinical Investigation 30 729-739. (doi:10.1046/j.1365-2362.2000. 00700.x)
23. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL & Ajani JA 2008 Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon a-2b. Journal of Clinical Oncology 26 1316-1323. (doi:10.1200/JCO.2007.13.6374)
24. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
25. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)